AI Engines For more Details: Perplexity Kagi Labs You
Dryness and Irritation: Isotretinoin commonly causes dryness and irritation of the skin, lips, eyes, and mucous membranes. Patients may experience dry skin, chapped lips, itching, redness, and sensitivity to sunlight.
Musculoskeletal Effects: Isotretinoin can cause musculoskeletal symptoms such as joint pain, muscle stiffness, and back pain. In rare cases, it may lead to musculoskeletal disorders such as arthritis or tendonitis.
Teratogenicity: Isotretinoin is highly teratogenic, meaning it can cause severe birth defects if taken during pregnancy. Female patients of childbearing potential must use highly effective contraception and adhere to strict pregnancy prevention measures before, during, and after isotretinoin therapy.
Psychiatric Effects: Isotretinoin has been associated with psychiatric side effects such as depression, mood changes, anxiety, aggression, and suicidal thoughts or behaviors. Patients should be monitored closely for signs of psychiatric disturbances during treatment.
Elevated Lipid Levels: Isotretinoin can increase blood lipid levels, including triglycerides and cholesterol, which may require monitoring and management, particularly in patients with underlying lipid disorders or cardiovascular risk factors.
Liver Function Abnormalities: Isotretinoin may affect liver function and lead to elevated liver enzymes. Regular monitoring of liver function tests is recommended during isotretinoin therapy.
Ocular Effects: Isotretinoin can cause dry eyes, blurred vision, and, rarely, more serious ocular side effects such as corneal opacities or decreased night vision.
Gastrointestinal Effects: Some patients may experience gastrointestinal side effects such as nausea, vomiting, abdominal pain, or inflammatory bowel disease exacerbation.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.1 | 0.1 | 0 |
Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | |
Allergies | 0.7 | 0.3 | 1.33 |
Allergy to milk products | 0.1 | 0.1 | 0 |
Alopecia (Hair Loss) | 0.1 | 0.1 | |
Alzheimer's disease | 0.4 | 0.4 | 0 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.4 | 0.75 |
Ankylosing spondylitis | 0.3 | 0 | 0 |
Anorexia Nervosa | 0.1 | -0.1 | |
Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
Asthma | 0.5 | -0.5 | |
Atherosclerosis | 0 | 0.1 | 0 |
Atrial fibrillation | 0.3 | 0.1 | 2 |
Autism | 1.2 | 0.8 | 0.5 |
Barrett esophagus cancer | 0 | 0 | |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 0.1 | 0.1 | 0 |
Brain Trauma | 0 | 0 | |
Carcinoma | 0.2 | 0.1 | 1 |
Celiac Disease | 0.1 | 0.3 | -2 |
Cerebral Palsy | 0.1 | 0.1 | 0 |
Chronic Fatigue Syndrome | 0.3 | 0.6 | -1 |
Chronic Kidney Disease | 0.1 | 0.2 | -1 |
Chronic Lyme | 0 | 0 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0 | 0.1 | 0 |
Chronic Urticaria (Hives) | 0.2 | 0.3 | -0.5 |
Coagulation / Micro clot triggering bacteria | 0.2 | 0.1 | 1 |
Colorectal Cancer | 0.3 | 0 | 0 |
Constipation | 0.1 | 0.1 | 0 |
Coronary artery disease | 0 | 0.2 | 0 |
COVID-19 | 0.8 | 0.9 | -0.13 |
Crohn's Disease | 0.7 | 0.5 | 0.4 |
cystic fibrosis | 0.2 | 0 | 0 |
deep vein thrombosis | 0.2 | 0.2 | |
Depression | 0.9 | 1 | -0.11 |
Eczema | 0.1 | 0.1 | 0 |
Endometriosis | 0.4 | 0.4 | |
Eosinophilic Esophagitis | 0 | 0 | |
Epilepsy | 0.4 | 0.5 | -0.25 |
Fibromyalgia | 0.1 | 0.3 | -2 |
Functional constipation / chronic idiopathic constipation | 0.2 | 0.2 | 0 |
gallstone disease (gsd) | 0.1 | 0 | 0 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.2 | -1 |
Generalized anxiety disorder | 0.3 | 0.1 | 2 |
Gout | 0.1 | -0.1 | |
Graves' disease | 0 | 0.1 | 0 |
Halitosis | 0 | 0 | |
Hashimoto's thyroiditis | 0.3 | 0 | 0 |
Hidradenitis Suppurativa | 0 | 0 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.1 | 1 |
hypercholesterolemia (High Cholesterol) | 0.3 | -0.3 | |
hyperglycemia | 0.1 | 0.5 | -4 |
Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 0.2 | 0.4 | -1 |
Hypothyroidism | 0.2 | -0.2 | |
Hypoxia | 0.2 | 0.2 | |
Inflammatory Bowel Disease | 0.2 | 0.8 | -3 |
Insomnia | 0.1 | 0 | 0 |
Intelligence | 0.1 | 0.1 | |
Intracranial aneurysms | 0.1 | 0.1 | |
Irritable Bowel Syndrome | 0.5 | 0.3 | 0.67 |
Liver Cirrhosis | 0.5 | 0.3 | 0.67 |
Long COVID | 0.8 | 0.5 | 0.6 |
Low bone mineral density | 0.1 | -0.1 | |
Lung Cancer | 0.1 | 0.4 | -3 |
ME/CFS with IBS | 0.2 | 0.4 | -1 |
ME/CFS without IBS | 0.1 | 0 | 0 |
Metabolic Syndrome | 0.6 | 0.7 | -0.17 |
Mood Disorders | 1.3 | 1 | 0.3 |
multiple chemical sensitivity [MCS] | 0.1 | 0.1 | 0 |
Multiple Sclerosis | 0.5 | 0.1 | 4 |
Multiple system atrophy (MSA) | 0.4 | 0.1 | 3 |
Neuropathy (all types) | 0.2 | 0.1 | 1 |
neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 0.8 | -7 |
Obesity | 0.4 | 0.7 | -0.75 |
obsessive-compulsive disorder | 0.8 | 0.5 | 0.6 |
Osteoarthritis | 0.1 | 0.1 | |
Osteoporosis | 0.1 | 0.4 | -3 |
Parkinson's Disease | 0.7 | 0.4 | 0.75 |
Polycystic ovary syndrome | 0.2 | 0.1 | 1 |
Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
Premenstrual dysphoric disorder | 0.1 | 0.1 | |
Psoriasis | 0.4 | 0.4 | 0 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.5 | 0.2 | 1.5 |
Schizophrenia | 0.4 | 0.2 | 1 |
scoliosis | 0.1 | 0.1 | |
Sjögren syndrome | 0.1 | 0.1 | 0 |
Sleep Apnea | 0.2 | 0.2 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
Stress / posttraumatic stress disorder | 0.3 | 0.4 | -0.33 |
Systemic Lupus Erythematosus | 0.4 | 0.1 | 3 |
Tourette syndrome | 0.1 | 0 | 0 |
Type 1 Diabetes | 0.3 | 0.3 | |
Type 2 Diabetes | 0.6 | 0.8 | -0.33 |
Ulcerative colitis | 0.3 | 0.6 | -1 |
Unhealthy Ageing | 0.8 | 0.3 | 1.67 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.